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Information on the molecular basis of 
cystic kidney disease in general and 
autosomal dominant polycystic kid-
ney disease (ADPKD) in particular 
has increased spectacularly over the 
past decade, and there is impetus to 
translate this new knowledge into new 
treatments.1 Parker et al.2 (this issue) 
report an abnormal response to insu-
lin-like growth factor-1 (IGF-1) by 
immortalized ADPKD cells growing in 
culture; this response is characterized 
by an excessive proliferative response 
and an increase in cyclic adenosine 3’, 
5’ monophosphate (cAMP) levels. Th e 
proliferative response can be halted by 
inhibition of the activities of either Ras 
or Raf. Th is study suggests a new avenue 
of treatment for ADPKD: arrest of the 
proliferative phase of the disease, which 
precedes cyst formation, by blockade 
of the Ras or Raf activities elicited by 
IGF-1 signaling.
Drugs that inhibit molecular targets for 
specifi c diseases — such as ADPKD — 
may have additional eff ects, including 
activation of other downstream signaling 
pathways and unexpected stimulation of 
cytokine production or of growth-factor 
cascades, or have deleterious eff ects in 
healthy surrounding tissues. ADPKD, 
and renal cystic diseases in general, 
resemble benign neoplasias more than 
any other renal diseases do. Hence, in 
principle, it makes sense to treat these 
diseases by preventing or limiting the 
growth of cyst cells, or of the still ‘tubule 
cells’ destined by their mutation(s) to 
become cyst cells. ADPKD makes a 
better target for proliferation-blocking 
drugs than inflammatory or degen-
erative diseases, in which attempts to 
modify pathogenic phenotypes (such 
as apoptosis or fi brosis) risk injury to 
bystander normal cells and lack specifi -
city and effi  cacy because of the minor 
contributions of the target phenotype to 
the loss of nephron function.1
In the report by Parker et al.,2 it is 
of note that the abnormal response of 
ADPKD-derived cell lines to IGF-1 was 
not observed in normal cells, which had 
a lower proliferative rate. Th e challenge 
to devise new treatments involves the 
identifi cation of a signaling site, perhaps 
a node, where other signals concur, thus 
blocking cyst formation without injury 
to the normal cells, with the caveat that 
the ‘normal cells’ in ADPKD tubules do 
carry the genetic mutation.
ADPKD is a genetic disease caused 
by genomic mutations probably asso-
ciated with second-hit somatic muta-
tions of the PKD1 or PKD2 gene. Both 
genes code for integral membrane 
proteins, PC1 and PC2, respectively. 
Both proteins are expressed in cilia of 
renal-tubule cells (except intercalated 
cells). PC1 is also expressed in lateral-
membrane junctions, focal adhesions, 
and apical vesicles; PC2 is found in the 
endoplasmic reticulum, the basolateral 
membrane, and mitotic spindles. PC1 
and PC2 associate in the membrane and 
are thought to form a mechanosensor 
that modulates entry of Ca2+ (reviewed 
by Ong and Harris3).
Th e phenotype of ADPKD consists, 
fundamentally, of the formation of 
cysts originated in tubule-kidney cells. 
Th e cysts separate from the originating 
tubule and grow by proliferation of the 
epithelial cells that form the wall. Th e 
cyst epithelium secretes fl uid by a Cl–-
secretory mechanism. During the cyst’s 
expansion, the surrounding normal kid-
ney tissues are destroyed by a process 
involving fi brocytic transdiff erentiation 
of epithelial cells, collagen deposition, 
infl ammatory changes, and pruning of 
the vasculature4 (reviewed by Calvet and 
Grantham5 and Wilson6). Th e pathogen-
esis of ADPKD is not fully understood. 
Polycystins 1 and 2 are involved in 
numerous signaling pathways, and the 
interaction between them involves coop-
erative and inhibitory eff ects (reviewed 
by Ong and Harris3).
Mutations of either PC1 or PC2 change 
normal signaling mechanisms, resulting 
in increased tubule-cell proliferation 
and modifying the transepithelial ion-
transport mechanism, thus causing fl uid 
secretion. The link between disease-
causing mutations and the activation of 
cystogenesis is still unclear. Th e cystic 
phenotype has been related to the hypo-
haploidism of PC1 as well as to the over-
expression of PC1 (reviewed by Ong and 
Harris3). Mutations of a large number of 
ciliary proteins also conduce to the cystic 
Inhibition of tubule-cell 
proliferation to prevent cyst 
formation: a new avenue to treat 
ADPKD?
E Bello-Reuss1
Tubule-cell hyperproliferation precedes cyst development in 
autosomal dominant polycystic kidney disease (ADPKD). Parker 
et al. report that insulin-like growth factor-1 stimulates ADPKD 
cell proliferation by activating Ras and Raf; inhibition of Ras or Raf 
abolished this effect. Inhibiting tubule-cell proliferation could halt 
cyst formation and prolong survival of functional tubules, offering a 
new treatment for ADPKD patients.
Kidney International (2007) 72, 135–137. doi:10.1038/sj.ki.5002377
1Texas Tech University Health Science Center, 
Internal Medicine, Division of Nephrology and 
Hypertension, Lubbock, Texas, USA
Correspondence: E Bello-Reuss, Texas Tech 
University Health Science Center, Internal 
Medicine, Division of Nephrology and 
Hypertension, Room 4B234, 3601 4th Street, 
Lubbock, Texas 79430, USA. 
E-mail: elsa.bello-reuss@ttuhsc.edu
136   Kidney International (2007) 72
commentar y
phenotype in humans and animal mod-
els, suggesting the possibility of a con-
verging cystogenic pathway (reviewed 
by Simons and Walz7). Th e study of the 
mechanisms of abnormal proliferation of 
tubule cells and cyst cells in PKD animal 
models, and of ADPKD cyst cells in cul-
ture, has identifi ed already numerous tar-
get sites amenable to treatment (reviewed 
by Walz8). Some of these are the renal 
vasopressin receptor, the somatostatin 
receptor, and the protein kinase mTOR.8 
Pharmacological inhibition of these mol-
ecules appears to reduce tubule-cell pro-
liferation and cystogenesis. Th e study by 
Parker et al.2 provides exciting results 
implicating an abnormal response to 
IGF-1 in the triggering of cell prolifera-
tion of human tubule cells carrying well-
documented ADPKD mutations.
A critical step toward the development 
of the cystic phenotype may reside in the 
perturbation of the PC1–PC2 complex 
response to tubule-fluid flow. Cessa-
tion of fl ow sensing results in a decrease 
in intracellular Ca2+, the normal Ca2+ 
level necessary for the maintenance of 
the tubule phenotype of the epithelium, 
which involves controlled proliferation 
and maintenance of the normal ion-
transport mechanisms.
Seminal contributions by Grantham 
(reviewed by Torres9) demonstrated 
that cAMP is involved in both cell 
proliferation and cyst-fl uid secretion. 
Key to these fi ndings is an abnormality in 
the response to cAMP (as compared with 
normal tubule cells), which involves acti-
vation of the extracellular signal-regu-
lated kinase (ERK) cascade and increased 
proliferation. Further, treatment of col-
lecting duct cells with calcium-chan-
nel blockers results in an abnormal, 
proliferative response. Th e accumula-
tion of cAMP seems to be a factor com-
mon to cystic disease in rodent models 
(reviewed by Torres9). Th e mechanism of 
the increase in cAMP levels in ADPKD 
cells is still incompletely understood. In 
normal conditions, binding of the C-
terminal tail of PC1 to heterotrimeric G 
proteins initiates inhibitory signals; dis-
ruption of this suppressive mechanism 
may increase cellular cAMP. In addition, 
the reduction in intracellular Ca2+ stim-
ulates Ca-inhibitable adenylyl cyclases 
and inhibits phosphodiesterases, which, 
in turn, are inhibited by ERK2, a kinase 
known to be elevated in ADPKD.
It is also known that aquaporin 2 and 
the vasopressin receptor are upregulated 
in animal models of PKD. Th ese obser-
vations have prompted the successful 
treatment of animals and the initiation 
of clinical trials with OPC31260, a vaso-
pressin receptor antagonist that lowers 
cAMP and inhibits cyst development 
in rodents.
Parker et al.2 examined the down-
stream signaling events induced by 
IGF-1 stimulation in vitro using sev-
eral unique kidney cell lines derived 
from patients with defined germline 
PKD1 mutations, providing an excellent 
model to study the signaling cascades 
in cells that genetically and apparently 
phenotypically reproduce the human 
disease. Growth-factor overproduc-
tion and receptor overexpression are 
known mechanisms of tumor-cell 
growth. In PKD animal models, the 
expression of IGF-1 is increased; also, 
in PKD, proliferating cells are detected 
frequently in tubule segments of nor-
mal diameter and rarely in larger cysts, 
suggesting that proliferative activity is 
an early event leading to the acquisi-
tion of a cystic phenotype. On the basis 
of these two observations, the authors 
demonstrated that IGF-1 dramatically 
increased ADPKD cell proliferation 
and that this eff ect was not present in 
normal tubule cell lines. Th e latter is a 
crucial point, because it may be possi-
ble to design a pharmacological treat-
ment that will arrest proliferation of 
cells already committed to cyst forma-
tion, but not of normal cells. However, 
‘normal’ tubule cells in ADPKD patients 
carry the genetic mutation, and whether 
their response to drugs that inhibit pro-
liferation will be diff erent from that of 
mutant cells remains to be determined.
Importantly, the ADPKD cell lines 
studied showed a reduction or absence 
of polycystin-1 but normal polycystin-
2 expression. It has been proposed that 
there is an inverse correlation between 
the level of PC1 expression and cell pro-
liferation, and the study by Parker et al.2 
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Figure 1 | Downstream signaling events, induced by insulin-like growth factor-1 in ADPKD 
epithelial cells, that lead to cell hyperproliferation.2 Inhibition of Ras or Raf abolishes 
cell proliferation stimulated by insulin-like growth factor-1 (IGF-1). Cyclic adenosine 3’, 5’ 
monophosphate (cAMP) may play a permissive role in the stimulation of ADPKD epithelial-cell 
proliferation. dbcAMP, dibutyryl cAMP; ERK, extracellular signal regulated kinase; MEK, mitogen-
activated protein kinase kinase; PDE, phosphodiesterase; PI3K, phosphatidylinositol-3′-kinase; PKA, 
protein kinase A; siRNA, small interfering RNA.
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supports this assertion by showing that 
polycystin-1 defi ciency was associated 
with increased sensitivity to IGF-1 as 
well as a permissive eff ect of cAMP on 
cell growth. Th e increase in cell prolif-
eration in response to both agents was 
found to be dependent on phosphati-
dylinositol-3′-kinase and ERK activity. 
It was reported previously that epider-
mal growth factor and cAMP regulate 
cell proliferation in ADPKD cystic cells, 
but, in contrast to IGF-1 in the report by 
Parker et al.,2 the mitogenic response to 
epidermal growth factor was the same 
between normal and cystic cells.10 Th is 
may represent an additional advantage 
from the therapeutic point of view, pro-
vided that this new pathway ends up 
being the most important in the deter-
mination of cyst-cell proliferation.
Inhibition of either Ras or Raf abol-
ished cell proliferation stimulated by 
IGF-1. Ras activation assays revealed 
signifi cantly higher IGF-1-stimulated 
levels of GTP-Ras in cyst cells compared 
with control cells, but cAMP alone had 
no eff ect on GTP-Ras levels. Th e mecha-
nism by which Ras and Raf are activated 
remains unclear.
Although there are still many steps 
of the complicated signaling pathways 
downstream from the PC1–PC2 com-
plex that remain obscure, the results of 
Parker et al.2 strongly suggest that inhi-
bition of Ras or Raf activation could be 
a useful therapeutic approach to reduce 
tubule-cell proliferation in ADPKD, 
ideally inhibiting cyst formation, and 
perhaps prolonging survival of func-
tional tubules. Th e future looks prom-
ising, exciting, based on the hope that 
translation of these fi ndings to animal 
models and eventually to clinical trials 
will bring much-needed treatment to 
ADPKD patients.
REFERENCES
1. Nelson PJ, Shanki SJ. Therapeutics in renal 
diseases: the road ahead for antiproliferative 
targets. Nephron Exp Nephrol 2006; 103: e6–e15.
2. Parker E, Newby LJ, Sharpe CC et al. 
Hyperproliferation of PKD1 cystic cells is induced 
by insulin-like growth factor-1 activation of the 
Ras/Raf signalling system. Kidney Int 2007; 72: 
157–165.
3. Ong ACM, Harris PC. Molecular pathogenesis of 
ADPKD: the polycystin complex gets complex. 
Kidney Int 2005; 67: 1234–1247.
4. Wei W, Popov V, Walocha JA et al. Evidence of 
angiogenesis and microvascular regression in 
autosomal-dominant polycystic kidney disease 
kidneys: a corrosion cast study. Kidney Int 2006; 
70: 1261–1268.
5. Calvet JP, Grantham JJ. The genetics and 
physiology of polycystic kidney disease. Semin 
Nephrol 2001; 21: 107–123.
6. Wilson PD. Polycystic kidney disease. N Engl J Med 
2004; 358: 151–164.
7. Simons M, Walz G. Polycystic kidney disease: cell 
division without a c(l)ue? Kidney Int 2006; 70: 
854–864.
see original article on page 202
Emerging role for fetuin-A as 
contributor to morbidity and 
mortality in chronic kidney 
disease
R Mehrotra1,2
Vascular calcification (VC) is an important reason for the high burden 
of vascular disease among chronic dialysis patients. Chronic kidney 
disease (CKD) is associated with increased promoters and decreased 
inhibitors of VC. The circulating levels of fetuin-A, a well-described 
inhibitor of calcification, regulate the cell-dependent process of 
osteogenesis. It is not surprising that the low circulating fetuin-A 
levels are associated with a greater prevalence and/or severity of 
VC and increased risk for all-cause and cardiovascular mortality. 
However, high circulating fetuin-A levels appear to induce insulin 
resistance and, in non-dialyzed subjects with diabetic nephropathy, 
are directly related to VC burden. These findings underscore the need 
to further clarify the multiple, systemic effects of fetuin-A and its role 
in health and various stages of CKD.
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Maintenance dialysis patients experi-
ence considerable morbidity and have 
a high mortality rate, particularly from 
vascular diseases. Accelerated vascular 
calcifi cation (VC) is but one of the sev-
eral important pathobiologic mecha-
nisms that contribute to the high burden 
of vascular disease in dialysis patients. 
In the setting of chronic kidney disease 
(CKD), VC is more severe and prevalent 
in both the intima and the media of the 
blood vessels — the former invariably 
occurs in the setting of atherosclero-
sis.1 It should be noted that none of the 
currently available noninvasive tools 
for the assessment of VC can reliably 
distinguish intimal from medial calci-
fi cation. Th us, in most human studies, 
the ascertained VC is a composite of 
intimal and medial calcifi cation.1 It had 
